Initial treatment strategies and treatment details for those treated with steroids
| Type 1 AIP (n=901†) | Type 2 AIP (n=85†) | ||||
|---|---|---|---|---|---|
| Successful remission, n | % | Successful remission, n | % | ||
| Initial treatment | |||||
| Steroids | 681/684 | 99.6 | 48/52 | 92.3 | |
| Surgical resection | 125/127 | 98.4 | 17/25 | 68.0 | |
| Palliative surgical bypass | 22/23 | 95.7 | 1/2 | 50.0 | |
| Conservative | 37/67 | 55.2 | 4/6 | 66.7 | |
| Type 1 AIP (n=724) | Type 2 AIP (n=53) | ||||
| n | % | n | % | p Value* | |
| Indications for steroid treatment | |||||
| Jaundice | 458 | 63 | 13 | 25 | <0.001 |
| Pancreatitis/abdominal pain | 198 | 27 | 34 | 64 | <0.001 |
| Abnormal imaging (diffuse pancreatic enlargement, pancreas mass) | 71 | 10 | 0 | – | 0.01 |
| Salivary gland enlargement | 49 | 7 | 0 | – | 0.04 |
| Diagnostic steroid trial | 46 | 6 | 4 | 8 | 0.77 |
| Retroperitoneal fibrosis | 17 | 2 | 0 | – | 0.62 |
| IgG4-related renal disease | 9 | 1.2 | 0 | – | 0.99 |
| Lymphadenopathy | 6 | 0.8 | 0 | – | 0.99 |
| IgG4-related lung disease | 4 | 0.6 | 0 | – | 0.99 |
| Inflammatory bowel disease | 1 | 0.1 | 23 | 48 | <0.001 |
| Other (hyperglycaemia, weight loss, etc) | 20 | 3 | 0 | – | |
| Diabetes management | |||||
| Oral medications | 99/596 | 17 | 6/46 | 13 | 0.53 |
| Insulin therapy | 136/596 | 23 | 4/46 | 9 | 0.03 |
| Endoscopic management (for subjects with jaundice) | |||||
| Biliary stent placement | 351/492 | 71 | 10/13 | 77 | 0.77 |
*p Values represent comparison of proportions between patients with type 1 and type 2 AIP using χ2 and Fisher's exact t test, when appropriate.
†Seventy-seven subjects with type 1 AIP and one subject with type 2 AIP are not displayed in the table due to pending response to treatment at study closure.
AIP, Autoimmune pancreatitis.